Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
50
HIMS Quote, Financials, Valuation and Earnings
Last price:
$27.65
Seasonality move
:
21.09%
Day range:
$26.36 - $28.20
52-week range:
$8.14 - $35.02
Dividend yield:
0%
P/E ratio:
61.14x
P/S ratio:
4.93x
P/B ratio:
13.36x
Volume:
9M
Avg. volume:
14.6M
1-year change:
222.16%
Market cap:
$5.9B
Revenue:
$872M
EPS (TTM):
$0.44
Analysts' Opinion
-
Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $25.21, Hims & Hers Health has an estimated downside of -6.28% from its current price of $26.90.
-
Price Target UpsideAccording to analysts, the highest upside price target is $38.00 representing 41.26% upside increase from its current price of $26.90.
Fair Value
-
According to the consensus of 9 analysts, Hims & Hers Health has -6.28% downside to fair value with a price target of $25.21 per share.
HIMS vs. S&P 500
-
Over the past 5 trading days, Hims & Hers Health has underperformed the S&P 500 by -0.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Hims & Hers Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hims & Hers Health has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hims & Hers Health reported revenues of $401.6M.
Earnings Growth
-
Hims & Hers Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hims & Hers Health reported earnings per share of $0.32.
Enterprise value:
5.6B
EV / Invested capital:
--
Price / LTM sales:
4.93x
EV / EBIT:
131.05x
EV / Revenue:
4.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
37.58x
Price / Operating cash flow:
40.94x
Enterprise value / EBITDA:
99.36x
Gross Profit (TTM):
$1B
Return On Assets:
21.22%
Net Income Margin (TTM):
8.15%
Return On Equity:
27.83%
Return On Invested Capital:
27.83%
Operating Margin:
5.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $444.4M | $792.6M | $1.2B | $226.7M | $401.6M | |
| Gross Profit | $338.5M | $643.2M | $1B | $187.3M | $317.9M | |
| Operating Income | -$78.7M | -$40.7M | $42.9M | -$8.6M | $22.4M | |
| EBITDA | -$71.6M | -$31.8M | $56.6M | -$6.2M | $26.8M | |
| Diluted EPS | -$0.42 | -$0.17 | $0.44 | -$0.04 | $0.32 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $107.1M | $274.2M | $233.5M | $250.2M | $326.4M | |
| Total Assets | $119.2M | $420.1M | $382.8M | $413.9M | $602.3M | |
| Current Liabilities | $17M | $52.5M | $66.8M | $82.5M | $152.6M | |
| Total Liabilities | $262.5M | $64.9M | $71.9M | $85.3M | $162.2M | |
| Total Equity | -$143.3M | $355.2M | $310.9M | $328.6M | $440.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.9M | $44.8M | $186.7M | $25.2M | $85.3M | |
| Cash From Investing | $38.9M | -$26.8M | $18.9M | -$31.1M | -$10.4M | |
| Cash From Financing | -$22.7M | -$18M | -$98.2M | -$1.6M | -$38.8M | |
| Free Cash Flow | -$29M | $26.9M | $149.6M | $19.3M | $79.4M | |
HIMS
Sector
Market Cap
$5.9B
$48.9M
Price % of 52-Week High
76.81%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
2%
-0.74%
1-Year Price Total Return
222.16%
-30.56%
Beta (5-Year)
1.309
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$26.41
200-day SMA
Buy
Level
$19.75
Bollinger Bands (100)
Buy
Level
16.07 - 27.59
Chaikin Money Flow
Sell
Level
-25.1M
20-day SMA
Sell
Level
$28.52
Relative Strength Index (RSI14)
Sell
Level
48.51
ADX Line
Sell
Level
20.3
Williams %R
Neutral
Level
-69.103
50-day SMA
Buy
Level
$26.41
MACD (12, 26)
Sell
Level
-0.44
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Sell
Level
-1.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.8017)
Buy
CA Score
(Annual)
Level (1.4881)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (0.0695)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Stock Forecast FAQ
In the current month, HIMS has received 2 Buy ratings 7 Hold ratings, and 0 Sell ratings. The HIMS average analyst price target in the past 3 months is $25.21.
-
Where Will Hims & Hers Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hims & Hers Health share price will drop to $25.21 per share over the next 12 months.
-
What Do Analysts Say About Hims & Hers Health?
Analysts are divided on their view about Hims & Hers Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hims & Hers Health is a Sell and believe this share price will rise from its current level to $18.00.
-
What Is Hims & Hers Health's Price Target?
The price target for Hims & Hers Health over the next 1-year time period is forecast to be $25.21 according to 9 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is HIMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hims & Hers Health is a Hold. 7 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HIMS?
You can purchase shares of Hims & Hers Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hims & Hers Health shares.
-
What Is The Hims & Hers Health Share Price Today?
Hims & Hers Health was last trading at $27.65 per share. This represents the most recent stock quote for Hims & Hers Health. Yesterday, Hims & Hers Health closed at $26.90 per share.
-
How To Buy Hims & Hers Health Stock Online?
In order to purchase Hims & Hers Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
